ON-DEMAND WEBINAR
Accelerating Oligonucleotide-based Therapies: Advancements in Detection and Localization
Join Peter Oliver, PhD, Head of Biology at the Nucleic Acid Therapy Accelerator (NATA), alongside Dr. Carl Ascoli, Chief Science Officer at Rockland, to explore advanced techniques in oligonucleotide drug delivery and detection. The discussion will focus on how Rockland's ModDetect anti-PS and anti-MOE Panels are enhancing the precise detection of RNA therapeutic modalities including antisense oligonucleotides (ASOs) and siRNA, offering significant improvements in the elucidation of ADMET profiles of potential therapeutics.
The webinar will cover detection and characterization data from the synthesis and modification of oligonucleotides using sophisticated chemistries like PS, 2’-O-MOE, 2’-O-Me, and LNAs, among others, highlighting their roles in improving molecular stability and affinity essential for therapeutic efficacy. Additionally, the webinar will delve into in vitro and in vivo applications demonstrating the effectiveness of these therapies across various biological models, supported by Rockland’s innovative detection tools.
Key topics include:
Practical applications of Rockland's ModDetect anti-PS and MOE antibody panels in RNA therapeutic research
Challenges in drug delivery systems, particularly in achieving efficient endosomal escape
The role of rigorous in vitro and in vivo testing in validating the safety and efficacy of oligonucleotide therapeutics
Opportunities for future collaboration in advancing nucleic acid therapeutic research
Date: June 5, 2024 @ 10:00-11:00 am EST
Presenters:
Peter Oliver, PhD
Head Of Biology, NATA and Associate Professor of Neuroscience, University of Oxford
Peter Oliver has over 25 years of experience in mammalian molecular genetics, combining cell biology with mouse models of human disease to study novel gene function and dysfunction. In February 2022, he joined NATA as Head of Biology. NATA is an academic Medical Research Council Unit funded by £30M from the UK government to facilitate nucleic acid therapeutics across all disease areas, combining the latest methods in chemistry and biology.
Carl Ascoli, PhD
Chief Science Officer - Rockland
Dr. Carl Ascoli brings over 30 years of experience to Rockland and is responsible for leading teams in production, research, quality, and service. His guidance has led to the development of thousands of antibodies, many of which have been translated into assays and biomarker discoveries for cancer and other areas of research.